Amlodipine + indapamide + valsartan is under clinical development by Ahn-Gook Pharmaceutical and currently in Phase III for Idiopathic (Essential) Hypertension. According to GlobalData, Phase III drugs for Idiopathic (Essential) Hypertension does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Amlodipine + indapamide + valsartan LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Amlodipine + indapamide + valsartan overview
AG-1705 is under development for the treatment of idiopathic (essential) hypertension. It is an Incrementally modified drug. The drug candidate is a combination of amlodipine, indapamide, valsartan. It is administered through oral route. Amlodipine acts as calcium channel blocker, indapamide acts by targeting potassium channel and valsartan acts by targeting type 1 angiotensin II receptor.
Ahn-Gook Pharmaceutical overview
Ahn-gook Pharmaceutical (Ahn-gook Pharm) develops and markets pharmaceutical products. The company’s products include health function food, generic medicine, over-the-counter drugs, ethical drugs, and quasi-drugs among others. It is also developing various drug candidates at the clinical stage for therapeutic areas of the immune system, endocrine system, immune-oncology, cardiovascular system, respiratory system, and digestive system. Ahn-gook Pharm sells products in the form of tablets, capsules, creams, ointments, syrups, kits, and powder, among others. The company markets products under the brand name Ahngook. Ahn-gook Pharm is headquartered in Seoul, South Korea.
For a complete picture of Amlodipine + indapamide + valsartan’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
